Dear critical reader, as humanity hurtles into the AI-era, with its many exciting positive nation-building tipping-points, ...

Drug allergy labels (DAL) are common and largely unevaluated in children with primary immunodeficiencies, which could lead to worse patient outcomes, according to new research being presented at the ...

Q4 2025 Earnings Call February 10, 2026 6:45 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...

Sertraline is one of the most prescribed antidepressants, and many people take it for years. Most side effects stay mild, especially during the first weeks. However, a small group of reactions ...

Statin use had a statistically significant protective effect against acute asthma exacerbations in mild asthma among Black ...

Investing.com -- Upstream Bio (NASDAQ:UPB) stock fell 23% after the company reported mixed results from its Phase 2 VALIANT trial of verekitug for severe asthma treatment.

Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.

The cost profile of single maintenance and reliever therapy, also known as SMART or single-inhaler therapy, was “favorable” ...

A phase 2 asthma study of Upstream Bio’s TSLP receptor agonist has hit its primary endpoint. But with only the 12-week ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory ...

Budesonide–formoterol reliever therapy significantly reduces airway inflammation vs SABA in adults with mild to moderate asthma using ICS.